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Abstract
New guidelines for the collection and use of human tissues for research will impose new
requirements on researchers to seek ethical approval and patient consent. This extends to
the use of surplus tissue, such as breast cancer excision biopsies, which, until recently, have
been regarded as having been ‘abandoned’ by the patient. This article argues that some of
these new constraints provide hurdles to translational research that are unnecessary for
patient protection. This is particularly significant when emerging technologies are expected
to elicit major advances in clinical cancer research.
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Introduction
Characterization of the molecular constituents of cancer
and of the relationship of genotypic and phenotypic fea-
tures to the clinical behaviour of the disease(s) are of
enormous contemporary interest. This activity is fuelled by
the exponential rate of discovery of new genes, an increas-
ing understanding of the biological consequences of their
expression, and a recognition that application of this
knowledge in the clinic should provide the opportunity for
individually optimized therapeutic approaches.
Additionally, tumours may be explored as a primary
research material in their own right, which is probably best
epitomized by the recently announced Cancer Genome
Project [1], in which the aim is to establish all of the geno-
typic defects of a selection of human carcinomas. The
rapidly approaching completion of the Human Genome
Project may be expected to extend the number of
candidate genes for clinical evaluation by several orders of
magnitude. Some of the new analytical tools required are
already in place (although they need substantial refine-
ment to keep pace) to handle this vast amount of new
information in a miniaturized manner (eg DNA arrays and
tissue arrays enable the simultaneous analysis of the
expression of thousands of genes in a single sample, and
of the expression of a small number of genes in several
hundred tumours, respectively).
Excitement about the possible advances resulting from
molecular pathology has never been greater, and therefore
the imposition of restrictions on this work that unnecessar-
ily impede progress is of substantial concern.
Over the past few years there has been a perceived need
for official guidelines to ensure that access to and analysis
of tissues from patients can occur within a framework that
will not damage the individuals from whom the tissues
were collected and will free the clinical scientist fromBreast Cancer Research    Vol 2 No 4 Dowsett
concerns of litigation. It is therefore welcome that a
number of bodies have considered this matter and that
their views are available, at least in provisional or interim
form. The guidelines are well described in the accompany-
ing editorial [2], as they affect both the USA and UK. This
article argues that some of the guidelines will restrict
research activity by the increased number and height of
the hurdles imposed, and that it is important to assess
whether these restrictions are really necessary to safe-
guard the public both individually and as a whole.
The driving force behind the derivation of many of these
guidelines has been the advent of germline genetic
testing. It is clear that genetic research raises several dif-
ferent issues from those for nongenetic analyses. As such
it is reasonable to regulate genetic work in a way that
addresses the associated special issues. However, it
should be possible to apply such regulations without their
being an encumbrance to nongenetic research. It is
instructive to consider how the guidelines of the UK
Medical Research Council (MRC) [3] would impact on
one particularly active area of nongenetic clinical labora-
tory research.
Impact of guidelines on research
To address certain research questions relatively small sets
of tumours may be sufficient, and these may usually be
readily derived prospectively such that consenting of
patients is not a significant problem. However, in many
cases analysis of large numbers of tumours together with
associated, rigorously documented, full clinical histories is
required (eg assessing the clinical importance of new bio-
markers). This is particularly pertinent in breast cancer, in
which the disease and its treatment are exceptionally het-
erogeneous. Evaluation of biomarkers is uniquely informa-
tive when performed in association with large randomized
clinical trials, because this may allow the identification of
specific subsets of patients as benefiting or not benefiting
from a particular treatment. In these circumstances the
tissue to be accessed is that which is surplus to patholog-
ical diagnostic procedures.
Data derived from such studies not only assist in develop-
ing new criteria for patient–treatment selection, but may
also help in the identification of response and resistance
mechanisms and thereby direct new approaches to
therapy. The widespread recognition of the value of this
clinical scenario for such research is illustrated by the fact
that almost all clinical trials of a significant size now have
an associated correlative science committee dealing with
this specific issue.
In principal, it may be argued that the preferred approach
is to investigate the role of particular factors prospectively.
However, the follow-up time required for the clinical end-
points to mature is generally prohibitive to the conduct of
such prospective studies. Additionally, with new potential
markers being identified it is inevitable that the selection of
analyses will change as a clinical trial progresses. Most
modern clinical trials need to be very large to have suffi-
cient statistical power, and as a result are almost always
multicentre (and frequently international).
For example, the current Anastrozole and Tamoxifen Alone
or Combined trial of adjuvant therapy in postmenopausal
breast cancer has recruited from 95 centres around the
UK (plus many more outside the UK). This trial has in fact
completed recruitment and may be able to collect tissues
under the less stringent guidelines relating to retrospec-
tive specimens. If such a trial were to be initiated under
the new MRC guidance [3], however, then for retrieval of
specimens to occur every one of the 95 centres would be
required to operate a consent procedure for pathological
research on its patients and to record the individual results
of that procedure. Additionally, as associated research
ideas develop, each of the local research ethics commit-
tees (RECs) will need to consider, presumably under the
guidance of a multicentre REC, the research analyses to
be conducted. As new analytes became assayable, the
protocol and ethical approval would need to be revisited
by the analyst, the multicentre REC and the local REC.
This type of work might be assisted by future clinical trials
requesting consent in a general form (eg for ‘biochemical’
analyses) at the time of recruitment, but it is not clear that
this general consent will satisfy all authorities. In addition,
for many studies associated and correlative research
questions are unclear at the time of the study, and the trial-
ists may be reluctant to perform this additional procedure
when there appears to be no immediate research goal.
The requirement for patient consent to analysis of this
surplus tissue and the involvement of numerous local
RECs lead to a substantial encumberance and extra
expense. As far as RECs are concerned, would it not be
sufficient for the clinical scientist to obtain local REC
approval at his/her local site, and presentation of certifica-
tion of approval be sufficient for the pathologist to release
tissue without recourse to each individual local REC?
Consent is such a fundamental component of clinical
practice and research that it seems heretical to question
its necessity, but it is appropriate to ask whether in this
context it is a real necessity or a political nicety. The need
for consent appears to derive in part from the recom-
mended change in the way in which we regard this
surplus tissue (ie from it being considered as ‘abandoned’
to it being seen as a ‘gift’). For the latter to be the case
there has to be documentation demonstrating that the
tissue is a gift, in essence a delivery note ‘from me to you’.
Is this change in the status of surplus tissue really
needed? It seems to me that there should be no public
unease if it was clear that an enforceable set of regulationshttp://breast-cancer-research.com/content/2/4/241
were in place to guide the use of such tissues. It is likely that
the large majority of those patients who would decide not to
consent to surplus pathological material being used for
research would do so out of ignorance or misunderstand-
ing. It should be sufficient to require that pathology laborato-
ries and other custodians of tissues receive certification of
REC approval before release of materials. In the latter cir-
cumstances the REC itself would be required to ensure that
the approaches of the particular project would cater suffi-
ciently for the individuals concerned, and in particular that
issues of confidentiality are dealt with satisfactorily.
Conclusion
Presented above is but one example of a type of study that
will be made substantially more difficult by the guidelines of
the MRC such that research, which could significantly
improve our understanding and treatment of breast cancer,
may be discouraged to the degree that it does not occur.
This is not to decry the work of the expert committees that
have debated these issues at length and provided these
guidelines. They have indeed asked for responses before
finalization such that modifications may be considered. It is
important that individuals and research organizations do
not merely accept these provisional guidelines, perhaps in
their relief that some have been derived, but examine care-
fully how they may affect their future research and address
any concerns to the respective body.
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